多乐彩购彩网:CAR-T Cell Therapy

江西体彩11选5多乐彩走势图今天 www.phcnlx.com.cn Two landmark events occurred for CAR-T cell therapy in 2017: two anti-CD19 CAR-T cells were approved by FDA for the therapy of acute lymphoblastic leukemia (ALL) and relapsed or refractory large B-cell lymphoma, respectively. From then, increasing number of researchers have been dedicated to CAR-T cell therapy research.
What is CAR-T cell therapy？It is a kind of cell immunotherapy featured by its distinct research procedures (depicted in Fig. 1): Peripheral blood is collected from the patient firstly. Then T cells are isolated and stimulated. The cells are cultured and expanded after genetically engineered to express chimeric antigen receptors (CARs), which can recognize a specific tumor associated antigen, such as CD19, BCMA and CD20. Finally, the CAR-T cells will go through quality control and are reinfused into the patient.
Sino Biological Inc. provides not only quality CAR-T cell therapy target proteins, but also varied research reagents for the whole process of CAR-T cell therapy, such as high-quality cytokines, T cell related FACS antibodies, T cell activation antibodies, cytokine ELISA kits, apoptosis detection kits, Sinofection tranfection reagents and Supernuclease.

Fig. 1 CAR-T Cell Therapy Procedures